TWI896547B - 用於治療cns病症之組合物及方法 - Google Patents
用於治療cns病症之組合物及方法Info
- Publication number
- TWI896547B TWI896547B TW109121938A TW109121938A TWI896547B TW I896547 B TWI896547 B TW I896547B TW 109121938 A TW109121938 A TW 109121938A TW 109121938 A TW109121938 A TW 109121938A TW I896547 B TWI896547 B TW I896547B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867618P | 2019-06-27 | 2019-06-27 | |
| US62/867,618 | 2019-06-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202114700A TW202114700A (zh) | 2021-04-16 |
| TWI896547B true TWI896547B (zh) | 2025-09-11 |
Family
ID=71728947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109121938A TWI896547B (zh) | 2019-06-27 | 2020-06-29 | 用於治療cns病症之組合物及方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552829B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990469A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7787635B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220038680A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114391019A (cg-RX-API-DMAC7.html) |
| AR (1) | AR119305A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020302748A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026462A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143509A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289172A (cg-RX-API-DMAC7.html) |
| MX (3) | MX2021015942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI896547B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020264509A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2009142594A1 (en) * | 2008-05-20 | 2009-11-26 | Umecrine Ab | The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders |
| WO2014169833A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| CN107936076A (zh) * | 2011-09-08 | 2018-04-20 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| SI3705488T1 (sl) | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| MY190408A (en) * | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CA3030420C (en) * | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| AU2018290348B2 (en) * | 2017-06-23 | 2024-04-04 | Ayikoe-Guy MENSAH-NYAGAN | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| EP3728285B1 (en) * | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| US12139508B2 (en) | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| IL312610B2 (en) * | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| CN111410678B (zh) | 2019-01-08 | 2023-02-28 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| WO2020210116A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210117A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| BR112021026447A2 (pt) | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
| EP4251634A1 (en) * | 2020-11-25 | 2023-10-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
-
2020
- 2020-06-29 JP JP2021577424A patent/JP7787635B2/ja active Active
- 2020-06-29 CN CN202080059463.9A patent/CN114391019A/zh active Pending
- 2020-06-29 MX MX2021015942A patent/MX2021015942A/es unknown
- 2020-06-29 TW TW109121938A patent/TWI896547B/zh active
- 2020-06-29 KR KR1020227002448A patent/KR20220038680A/ko active Pending
- 2020-06-29 US US17/620,226 patent/US12552829B2/en active Active
- 2020-06-29 BR BR112021026462A patent/BR112021026462A2/pt unknown
- 2020-06-29 AU AU2020302748A patent/AU2020302748A1/en not_active Abandoned
- 2020-06-29 CA CA3143509A patent/CA3143509A1/en active Pending
- 2020-06-29 EP EP20743476.2A patent/EP3990469A1/en active Pending
- 2020-06-29 WO PCT/US2020/040153 patent/WO2020264509A1/en not_active Ceased
- 2020-06-29 AR ARP200101836A patent/AR119305A1/es unknown
-
2021
- 2021-12-16 MX MX2024009926A patent/MX2024009926A/es unknown
- 2021-12-16 MX MX2024009925A patent/MX2024009925A/es unknown
- 2021-12-20 IL IL289172A patent/IL289172A/en unknown
-
2025
- 2025-01-05 JP JP2025000024A patent/JP2025060984A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2009142594A1 (en) * | 2008-05-20 | 2009-11-26 | Umecrine Ab | The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders |
| CN107936076A (zh) * | 2011-09-08 | 2018-04-20 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| WO2014169833A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021026462A2 (pt) | 2022-03-15 |
| IL289172A (en) | 2022-02-01 |
| MX2021015942A (es) | 2022-04-18 |
| WO2020264509A1 (en) | 2020-12-30 |
| US20220380405A1 (en) | 2022-12-01 |
| CA3143509A1 (en) | 2020-12-30 |
| US20230303616A9 (en) | 2023-09-28 |
| EP3990469A1 (en) | 2022-05-04 |
| AU2020302748A1 (en) | 2022-01-06 |
| KR20220038680A (ko) | 2022-03-29 |
| MX2024009926A (es) | 2024-08-22 |
| US12552829B2 (en) | 2026-02-17 |
| JP2025060984A (ja) | 2025-04-10 |
| MX2024009925A (es) | 2024-08-22 |
| TW202114700A (zh) | 2021-04-16 |
| AR119305A1 (es) | 2021-12-09 |
| JP7787635B2 (ja) | 2025-12-17 |
| JP2022538299A (ja) | 2022-09-01 |
| CN114391019A (zh) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI896548B (zh) | 用於治療cns病症之組合物及方法 | |
| TWI864010B (zh) | 神經活性類固醇及其組合物 | |
| JP7817214B2 (ja) | CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物 | |
| JP7787635B2 (ja) | Cns障害を治療するための組成物及び方法 | |
| JP7754725B2 (ja) | Cns障害を治療するための組成物及び方法 | |
| TWI892697B (zh) | 神經活性類固醇及其組合物 | |
| TWI886813B (zh) | 神經活性類固醇及其使用方法 | |
| CN115768781A (zh) | 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物 | |
| KR20230124916A (ko) | Cns 장애를 치료하기 위한 조성물 및 방법 | |
| BR122025013998A2 (pt) | Compostos ou seus sais farmaceuticamente aceitáveis, composição farmacêutica e usos relacionados | |
| BR122025013997A2 (pt) | Compostos ou seus sais farmaceuticamente aceitáveis, composição farmacêutica e usos relacionados |